Loading...

PAVM PAVMED INC Capital Structure Changes 8-K Filing

PVMD

PVM

PAVMED INC

(PAVM)

2025 8-K

Summary

Summary

Stock Offering Completion

Financial Results Update

Rights Offerings

Asset Acquisitions

Financial Statements

Financial Results

Equity Offering

Nasdaq Compliance Regained

Nasdaq Compliance Notice

Equity Exchange

Share Issuance Approval

Convertible Notes Sale

Debt Exchange Agreement

Financial Results

Deconsolidation Update

Financial Results

Annual Meeting of Stockholders

Earnings Reports

Investment Agreement

Investment in Veris Cancer ...

Agreement Extension

Agreements and Stock Sale

Amendment and Waiver

Distribution of Lucid Diagn...

Distribution of Shares

Investment Payment

Compliance regained with Na...

Reverse Stock Split

Financial Results Announcement

Compliance Extension Granted

Annual Meeting of Stockholders

Investment in Sunrise Labs

Regulation FD Disclosure

Special Meeting Approval

Termination of Agreement

Financial Results Announcement

Securities Purchase Agreement

Subscription Agreements for...

Termination of Management S...

Lucid Diagnostics Inc. Anno...

External Links:

On April 17, 2025, PAVmed Inc. entered into a Sales Agreement with Maxim Group LLC to sell up to $2,880,000 of its common stock, with a 3.0% commission for the agent. The proceeds will be used for working capital and general corporate purposes.

AI Assistant

PAVMED INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.